Business
Oncolytics Biotech® to Present at the Oncolytic Virotherapy Summit
Oncolytics Biotech® to Present at the Oncolytic Virotherapy Summit Canada New...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"\n\n\n\nOncolytics Biotech® to Present at the Oncolytic Virotherapy Summit\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\n\nCanada NewsWire\nCALGARY and SAN DIEGO, CA, Dec. 4, 2017\n\n\n\nDr. Matt Coffey, Oncolytics' President & Chief Executive Officer, to present on the clinical progress of using reovirus as an immuno-oncology viral agent to treat cancer\n\n\n\nCALGARY and SAN DIEGO, CA, Dec. 4, 2017 /CNW/ - Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company), a biotech company developing REOLYSIN®, also known as pelareorep, an intravenously delivered immuno-oncolytic virus that activates the innate and adaptive immune systems to turn 'cold' tumors 'hot', today announced that it will present at the Oncolytic Virotherapy Summit.  Dr. Matt Coffey, Oncolytics' President and Chief Executive Officer, will present on Wednesday, December 6 at 11:00 a.m. ET as part of a panel presentation and then present specifically on pelareorep in a Clinical Case Study presentation at 2:30 p.m. ET on the same day.  The conference takes place on December 5th, 6th and 7th in Miami, Florida.\n\n\"The Oncolytic Virotherapy Summit offers us another opportunity to highlight our extensive experience with pelareorep in the clinic and to illustrate its ability to induce an inflamed tumor phenotype amongst our peers and for potential partners,\" said Dr. Coffey. \"Our clinical experience with pelareorep has led us to favorable feedback from the FDA following our end-of-phase 2 meeting which helps us define a clear regulatory path in metastatic breast cancer and a single 400-patient phase 3 registration study. Our phase 3 protocol will be made available following evaluation and completion of discussions with clinical advisors, potential partners and the EMA.\"\n\nThe panel presentation: \"How Can We Improve The Efficacy of Oncolytic Virotherapies?\", also including management from PsiOxus Therapeutics, Vyriad and Replimune Group, will cover:\n\n\nViral modulation of the tumor microenvironment\nIncreasing the...